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Interferon block to HIV-1 transduction in
macrophages despite SAMHD1 degradation and
high deoxynucleoside triphosphates supply
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Abstract
Background: Interferon-α (IFN-α) is an essential mediator of the antiviral response, which potently inhibits both
early and late phases of HIV replication. The SAMHD1 deoxynucleoside triphosphate (dNTP) hydrolase represents
the prototype of a new antiviral strategy we referred to as “nucleotide depletion”. SAMHD1 depletes dNTP levels in
myeloid cells below those required for optimal synthesis of HIV viral DNA. HIV-2 and its SIVsm and SIVmac close
relatives encode a protein termed Vpx, which counteracts SAMHD1. The potentiality of IFN-α to cooperate with
nucleotide depletion has been poorly investigated so far. Here we wondered whether IFN-α affects SAMHD1
expression, Vpx-induced SAMHD1 degradation, Vpx-mediated rescue of HIV-1 transduction and the dNTP supply in
monocyte-derived macrophages (MDMs).
Results: IFN-α inhibited HIV-1 transduction in monocytes and in MDMs while SAMHD1 expression was not up-
regulated. Vpx triggered SAMHD1 degradation in IFN-α treated cells, and weakly restored HIV-1 transduction from the
IFN-α block. Vpx helper effect towards HIV-1 transduction was gradually inhibited with increasing doses of IFN-α. dNTP
levels were not significantly affected in MDMs and CD4+ primary activated T lymphocytes by IFN-α and, in correlation
with SAMHD1 degradation, restoration of dNTP levels by Vpx was efficient in MDMs treated with the cytokine. In
contrast, IFN-α inhibited Vpx-mediated SAMHD1 degradation in THP-1 cells, where, accordingly, Vpx could not rescue
HIV-1 transduction.
Conclusion: Our results suggest that the early antiviral effect of IFN-α results from a mechanism independent of
nucleotide depletion in MDMs. In addition, they indicate that the macrophage-like THP-1 cell line may provide a
system to characterize an IFN-α-induced cell response that inhibits Vpx-mediated SAMHD1 degradation.
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Background
To establish infections in vivo, type 1 and type 2 human
immunodeficiency viruses (HIV-1 and HIV-2) have to
face powerful cellular defense mechanisms including
both intrinsic and innate immunity [1,2]. In a simplistic
view, intrinsic immunity refers to the existence of
restriction factors that inhibit virus entry as soon as the
virus enters into the host cell, while innate immunity
refers to the establishment of an antiviral state mediated
by the production of IFN-α. However both phenomena are
tightly linked through at least the ability of IFN-α to stimu-
late the expression of restriction factors that counteract
HIV, including Trim5α, apolipoprotein B mRNA-editing
enzyme catalytic polypeptide-like 3 G (APOBEC3G) and
tetherin/Bone marrow stromal cell antigen 2 (BST-2/
CD317) [3-8].
The IFN-α response is the major host immune
response against viruses. Not only IFN-α enhances the
innate immune response through the upregulation of
antiviral cellular factors, but also IFN-α enhances adap-
tive immune responses. Evidence of IFN-α activity has
been found in HIV-1 infected patients in vivo, notably
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through the role of the plasmacytoid dendritic cells,
which detect viral RNA by Toll-like receptor 7 and sub-
sequently represent a major source of IFN-α production
[9]. IFN-α inhibits many steps of the viral life cycle,
including the early steps of HIV-1 infection by inhibiting
the accumulation of HIV-1 cDNA in monocyte-derived
macrophages (MDMs) and to a lesser extent in primary
CD4+ T cells [10-19]. IFN-γ is also detected at high
levels in HIV-1 infected patients but in contrast to IFN-α,
which can be expressed by all cells, IFN-γ is secreted by
specialized cells (T helper cells, cytotoxic T cells and NK
cells) [20]. Few reports indicate that it may also be a player
in the early steps of the viral life cycle [15,16].
Macrophages play an important role in HIV infection
[21]. They are infected in vivo and contribute to viral
dissemination and transmission to other targets such as
CD4+ T lymphocytes [21-25]. They also constitute a
viral reservoir, which contributes to the establishment of
latency making them critical players in the pathogenesis
and ideal targets for anti-HIV therapy. Remarkably,
intracellular factors like the recently identified SAMHD1
restriction factor drastically impair HIV infection in
myeloid cells including macrophages [26-29].
SAMHD1 was initially identified as the human
ortholog of the mouse gene Mg11, which is induced by
IFN-γ treatment in macrophages [30]. Whether IFN
upregulates SAMHD1 expression in human myeloid
cells is unclear. In monocytes, IFN-α was shown to in-
duce SAMHD1 expression [31]. However, another report
showed that SAMHD1 expression is not upregulated by
IFN-α, β or γ in monocyte-derived dendritic cells or pri-
mary T lymphocytes [32]. SAMHD1 has been proposed
to act as a negative regulator of the innate immune re-
sponse, analogous to Trex-1 [33]. Strikingly, mutations
in the genes encoding SAMHD1, Trex1 and RNase H2
are all associated with Aicardi Goutières syndrome, a
rare inflammatory encephalopathy characterized by
over-production of IFN-α [34,35].
SAMHD1 is a dGTP-dependent deoxynucleoside tri-
phosphates (dNTP) hydrolase [27,36,37]. By reducing
the pool of dNTP in myeloid cells, SAMHD1 inhibits
the reverse transcription step [27,32,38,39]. This mech-
anism of nucleotide depletion highlights previous data
showing how low dNTP concentrations in myeloid cells
limit HIV-1 infection [40-42]. Viruses from both the
HIV-1 and HIV-2/SIVsm lineages are sensitive to
SAMHD1, but only the HIV-2/SIVsm lineage has devel-
oped a weapon to counteract this host defense factor,
the Vpx auxiliary protein [26,28]. These last years, Vpx
was recognized as a viral protein that counteracts the
cellular environment during the early phases of infection
[43-48] until its cellular target was identified as being
SAMHD1 [26,28]. As for other viral auxiliary proteins,
Vpx usurps the activity of the Cul4A-based ubiquitin
ligase through the DCAF1 adaptor, to induce the
degradation of SAMHD1 [26,28,49]. Nucleotide deple-
tion appears as a powerful mechanism of defense in
quiescent cells that do not replicate their nuclear DNA,
including CD4+ quiescent T cells, where SAMHD1 also
restricts HIV-1 infection [38,39].
Here we explore the possibility that the IFN-α
response, on the one hand, and nucleotide depletion, on
the other hand, cooperate to counteract the infection in
the early steps of HIV-1 infection in MDMs. We present
evidence that SAMHD1 does not specifically contribute
to the early-IFN-α block towards HIV-1. Furthermore,
our results suggest that IFN-α does not affect the intra-
cellular levels of dNTP at doses that inhibit HIV-1
transduction.
Results and discussion
A limited role of SAMHD1 in the early antiviral block
mediated by IFN-α
We reasoned that Vpx -which depletes SAMHD1-
should rescue the early IFN-α block to HIV-1 transduc-
tion, if this block was the result of SAMHD1 activity.
Monocytes (Figure 1A) or MDMs (Figure 1B) from two
donors were treated for 24 hours with high doses of
IFN-α or IFN-γ (10 000 units/ml), thereafter cells were
incubated with empty or Vpx-containing viral-like parti-
cles (VLP X- or VLP X+) and infected with a GFP-
encoding HIV-1 virus. The percentage of infected (GFP
positive) cells was measured 3 days post-infection. HIV-1
transduction was inhibited by IFN-α in both cell types
and to a lesser extent by IFN-γ though the respective
effects of both IFN were difficult to assess because of
the low transduction efficiencies. Vpx dramatically
increased HIV-1 transduction as expected [45] and was
able to slightly rescue HIV-1 transduction from the
IFN-α inhibitory effects in correlation with SAMHD1 deg-
radation (Figure 1A and B and Additional file 1: Figure S1).
At lower doses of IFN-α, the rescue from the IFN-α
block by Vpx was still weak (Figure 1C, 1000 U/ml;
Figure 2A, 100 U/ml) despite undetectable levels of
SAMHD1 (Figure 1D, 1000U/ml IFN-α or γ, one repre-
sentative donor over three donors). Lower doses of
IFN-γ did not significantly affect HIV-1 transduction or
Vpx helper effect (Figure 1C), which led us to pursue
our study only with IFN-α. Of note, APOBEC3A levels
were efficiently increased by IFN-α as previously shown
[50,51], and were not decreased by Vpx (Figure 1D).
No change in SAMHD1 levels was observed in a time-
course experiment where macrophages were treated
with IFN-α or IFN-γ for different times, in contrast to
APOBEC3A levels used as a control (Figure 1E).
These preliminary results argue for the existence of
IFN-α induced anti-HIV interfering factors other than
SAMHD1, but did not rule out a role of SAMHD1 in
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the early innate response in macrophages. In case
SAMHD1 contributed to the IFN-α-block, we expected
the helper effect of Vpx toward HIV-1 to be magnified
under IFN-α treatment, which should be measurable by
an enhancement of the transduction ratio “+ Vpx” over
“- Vpx” (Vpx helper effect). Transduction efficiencies
using HIV-1 GFP-expressing vectors were very low,
namely in the presence of IFN-α, and precluded the
determination of such ratios (Figure 1). We therefore
transduced cells with a VSV-G pseudotyped HIV-1 lucif-
erase virus, which enabled accurate quantification.
Transduction was gradually inhibited with increasing
doses of IFN-α, as well as the helper effect of Vpx
toward HIV-1 transduction (Figure 3A). In parallel,
SAMHD1 degradation was obtained at every single dose
of IFN-α, while levels of APOBEC3A and ISG15, a
second interferon-induced protein, were increased
(Figure 3B). These results suggest that SAMHD1, which
is well expressed at a basal level, is unlikely an early
specific IFN-α-induced factor in macrophages. We
further transduced IFN-α-primed macrophages with
Vpx + VLP to trigger SAMHD1 proteasomal degradation
C
A
D
E
B
Figure 1 Vpx poorly rescues HIV-1 transduction in IFN-α-primed monocytes/MDMs despite SAMHD1 degradation. (A) Monocytes from
two donors were either mock treated, or treated with IFN-α or IFN-γ (10000 U/ml). After 24 h, cells were incubated with empty or Vpx-containing
VLP (X- and X+, respectively) for 2 h, and transduced with a VSV-G-pseudotyped GFP-encoding HIV-1 virus for 2 h at a multiplicity of infection
(MOI) of 1. Three days post-transduction, the percentage of infected cells (% GFP + cells) was measured by flow cytometry. ND: not detected.
(B) Same experimental procedure as in (A) performed with MDMs derived from the monocytes of the 2 donors presented in (A). (C) Same
experimental procedure as in (B) performed in MDMs of 2 different donors, except that the concentration of IFN-α and IFN-γ has been reduced
to 1000 U/ml. (D) SAMHD1 as well as APOBEC3A (A3A) protein levels were assessed by Western blot analysis from the cells in (C) two days post
transduction (one representative Western blot is shown). (E): Western blot analysis of SAMHD1 and A3A expression in MDMs from two donors
challenged or not (Ctrl) for the indicated periods with 1000 U/ml of IFN-α and IFN-γ.
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and subsequently infected the cells with a Vpx-deleted
GFP-encoding SIVmac virus, which is sensitive to
SAMHD1 restriction. Unlike in control cells, where Vpx
rescue was efficient, Vpx was unable to enhance SIV
transduction in IFN-α treated cells even at low doses of
IFN-α as previously reported (Figure 3C) [19,52,53].
Altogether, our results suggest that SAMHD1 does not
specifically contribute to the IFN-α-block toward HIV-1
transduction in macrophages.
The IFN-α block to HIV-1 transduction is not the result of
a change in dNTP levels
We expected Vpx to enhance the dNTP pool to the
same extent with or without IFN-α since SAMHD1 was
degraded in both conditions. This assumption was
directly explored by quantifying dNTP levels in MDMs
treated or not with IFN-α. A 100U/ml dose of IFN-α
was deliberately used to severely inhibit HIV-1 transduc-
tion without overwhelming the transduction pathway
(Figure 2A). IFN-α did not affect the basal pool of intra-
cellular dATP and dTTP, representative of the four
dNTP (Figure 2B, one out of three representative donor
data is shown). As expected, dATP and dTTP levels
were drastically enhanced in the presence of Vpx or a
2 mM deoxynucleoside (dNs) treatment (Figure 2B).
When cells were primed with IFN-α, neither Vpx nor
dNs efficiently restored HIV-1 transduction (Figure 2A),
though dNTP increase was still efficient in both condi-
tions (Figure 2B). Thus, on the one hand, Vpx efficiently
rescued dNTP levels under IFN-α treatment in correl-
ation with SAMHD1 degradation despite poorly rescuing
HIV-1 transduction. On the other hand, bypassing
SAMHD1 dNTP hydrolase activity by providing dNs did
not allow rescuing HIV-1 transduction from the IFN-α
block (Figure 2A and B). Altogether, these results
reinforce our conclusion that SAMHD1 does not con-
tribute to the early interferon block to HIV-1 transduc-
tion and further suggest that dNTP levels are likely
not targeted by IFN-α to establish this block in
macrophages.
Because activated CD4+ T lymphocytes contain a
higher amount of dNTP than macrophages, we won-
dered whether IFN-α would affect the dNTP pool in
primary T cells. HIV-1 transduction rates were lower in
primary CD4+ T cells (Figure 4A) than in Jurkat or
CEM T cell lines (respectively 83% and 40%, data not
shown). A 1000 U/ml dose of IFN-α had a modest effect
on the transduction rate, ranging from a 2 to 8-fold
decrease (Figure 4A). Despite this reduction, dNTP
levels were not affected (Figure 4B).
Altogether, our results suggest that nucleotide depletion
does not contribute to the early IFN block toward HIV-1
transduction in macrophages or in activated CD4+
T lymphocytes.
IFN-α inhibits Vpx-mediated SAMHD1 degradation in
THP-1 cells
Phorbol 12-myristate 13-acetate (PMA)-treated THP-1
cells recapitulate the MDMs phenotype in many aspects
and notably model MDMs in their sensitivity to Vpx-
containing VLP and Vpx-deleted SIV viruses. Surpris-
ingly, Vpx was unable to rescue HIV-1 transduction from
the IFN-α-block in these cells (Figure 5A and C, top)
unlike in primary MDMs. This lack of rescue correlated
with the inability of Vpx to induce the degradation of
SAMHD1 in IFN-α-treated THP-1 cells (Figure 5A and C,
bottom). Similar results were obtained with IFN-γ. The
levels of β-catenin, a very unstable protein, remained
A
B
Figure 2 The dNTP concentration in MDMs is not affected by
IFN-α doses that inhibit HIV-1 transduction. (A) MDMs
transduction was carried out as in Figure 1A. Cells were treated or not
with IFN-α (100 U/ml) for 24 h, then were incubated with empty or
Vpx-containing VLP (X- and X+, respectively) for 2 h. Finally, the cells
were transduced with a VSV-G-pseudotyped GFP-encoding HIV-1 virus
for 2 h (MOI 1). Exogenous deoxynucleosides (dNs) were used as
controls for further dNTP quantification. Three days post-transduction,
the percentage of infected cells (% GFP + cells) was measured by flow
cytometry. (B) dATP and dTTP levels were measured using the single
nucleotide-incorporation assay (three donors, one representative donor
data is shown). OR: out of range.
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unchanged under IFN-α or IFN-γ treatments, suggesting
that the inhibition of Vpx-mediated SAMHD1 degrad-
ation was not the result of an alteration of the
proteasomal degradation pathway (Figure 5A, bottom).
No rescue from the block was observed in SAMHD1-
depleted THP-1 cells [28] further demonstrating that
SAMHD1 did not contribute to the IFN block in THP-1
cells (Figure 5B). We further wondered why SAMHD1
was resistant to Vpx-mediated degradation in THP-1 cells.
We asked whether this effect was the result of an inhib-
ition of VLP entry using a β-lactamase-Vpr (BlaM-Vpr)
virion-based fusion assay. This test consists in the use
of viruses containing a BlaM-Vpr protein chimera. The de-
livery of BlaM-Vpr in the target cell is monitored by the en-
zymatic cleavage of a fluorogenic substrate of β-lactamase.
30% of decrease of viral entry was observed in the presence
of very high doses of IFN-α but not at lower doses that
remain sufficient to inhibit Vpx-mediated SAMHD1
degradation (Figure 5D and data not shown). Thus, a defect
in viral entry was not responsible for the inhibition of Vpx-
mediated SAMHD1 degradation in THP-1 cells. We
further wondered whether an effect of IFN-α on the
SAMHD1 promoter was at stake. To address this question,
we stably transfected cells with a retroviral vector encoding
HA-SAMHD1 under the control of the CMV promoter.
Interestingly, expression of exogenous SAMHD1 in THP-1
cells, which already express endogenous SAMHD1,
enhanced the restriction against HIV-1 by a 2-fold
(Figure 5C, top). HA-SAMHD1 was degraded in the pres-
ence of Vpx and this process was inhibited by IFN-α
(Figure 5C, bottom). This result suggests that inhibition of
Vpx-mediated SAMHD1 degradation does not depend on
an effect of IFN-α on the endogenous SAMHD1 promoter.
Furthermore no change in the levels of DCAF1 or DDB1,
subunits of the Cul4-based ubiquitin ligase used by Vpx,
was observed under IFN treatment (data not shown).
A
B C
Figure 3 Evidence that SAMHD1 does not contribute to the early IFN-α block to HIV-1 transduction. (A) IFN-α inhibits Vpx helper effect
toward HIV-1. MDMs were treated with increasing doses of IFN-α for 24 hours, incubated with empty or Vpx-containing VLP (X- or X+, respectively) for
2 h, then transduced with a VSV-G pseudotyped luciferase-encoding HIV-1 virus (HIV-1-Luc) normalized for infectivity, for 2 h. The transduction rate
(Luc activity) was measured 2 days post-transduction (left panel). Vpx helper effect corresponds to the fold increase of luciferase activity between cells
transduced with Vpx versus cells transduced without Vpx (right). The results shown are representative of three independent experiments. (B) Analysis
of SAMHD1, APOBEC3A and ISG15 expression in MDMs treated as in (A). (C) Vpx is unable to rescue SIVmac from the IFN-α block. MDMs were treated
with the indicated doses of IFN-α, incubated with empty or Vpx containing VLP (X- or X+, respectively) to trigger SAMHD1 degradation, before being
transduced with a Vpx-deleted SIVmac-GFP reporter virus (MOI 1). The percentage of transduction (% GFP + cells) was measured by flow cytometry
3 days post-transduction. The bar graph is representative of the results obtained in two independent experiments with different MDMs donors.
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Finally, we asked whether IFN-α treatment could perturb
SAMHD1 localization. Both endogenous SAMHD1 and
the stably expressed HA-tagged-protein were present in the
nucleus in agreement with previous reports [54-56]
(Figure 5E). Priming with IFN-α did not perturb this
localization.
Conclusions
Here we explore the potential interplay between the role
of IFN-α during the early steps of viral infection and the
mechanism of nucleotide depletion governed by
SAMHD1. We provide several lines of evidence that
SAMHD1 is unlikely a major contributor of the early
block imposed by IFN-α to HIV-1 transduction in
MDMs, indeed: (i) Vpx poorly rescues HIV-1 transduc-
tion from the IFN-α block; (ii) Vpx helper effect is
inhibited by increasing doses of IFN-α; (iii) SAMHD1
expression is not enhanced at IFN doses that inhibit
HIV-1 transduction; (iv) Vpx does not rescue a Vpx-
deleted SIV virus which is sensitive to SAMHD1 restric-
tion; (v) dNTP levels are not significantly affected under
IFN-α priming and are similarly increased by Vpx with
or without IFN-α. In contrast to our results, previous
data suggested that type I IFN magnified the effect of
Vpx toward HIV-1 transduction in MDMs [52]. These
previous findings suggested that the Vpx target was
IFN-inducible and that Vpx, as for other viral auxiliary
proteins, was able to escape some mechanisms of
innate immunity. At this time, SAMHD1 was not
discovered yet and whether SAMHD1 expression was
increased under IFN treatment could not be checked.
We do not understand why Vpx helper effect in MDMs
is magnified in one report and inhibited in our experi-
mental conditions. These discrepancies may result from
the different procedures followed to prepare macro-
phages, which may lead to the expression of different
potent antiviral factors that influence viral permissive-
ness. In any case, our results rule out a predominant
role of SAMHD1, or at least of the SAMHD1 dNTP
hydrolase activity, in the early IFN-α block to HIV-1
transduction. Indeed, despite no effect of IFN-α on
dNTP levels or SAMHD1 expression, HIV-1 transduction
was severely inhibited, highlighting the existence of other
anti-HIV interfering factors that contribute to the inter-
feron response [57]. The degradation of SAMHD1 does
not preclude these host factors from counteracting HIV.
A minor effect of SAMHD1 in the IFN block cannot how-
ever totally be discarded especially with the recent discov-
ery of its nuclease activity on nucleic acid substrates [58].
Whether Vpx triggers the degradation of host factors
other than SAMHD1 remains a subject of intense inves-
tigation. In addition to counteracting SAMHD1, Vpx has
been reported to induce the degradation of APOBEC3A,
a cellular factor known to exert its antiviral effect at the
step of viral DNA accumulation in HeLa cells and in
dendritic cells [59,60]. Here, in MDMs, we did not
observe APOBEC3A degradation in the presence of Vpx,
while SAMHD1 was degraded. As we were the only ones
to deliver Vpx to the cell with the use of VLP before
looking at APOBEC3A levels, it might be that only neo-
synthetized Vpx is able to trigger APOBEC3A degrad-
ation and not virion-packaged Vpx. This could result for
example from different levels of expression of Vpx from
one condition to the other. Alternatively, the resistance
of APOBEC3A to Vpx-induced degradation may also be
a specificity of MDMs. Interestingly, our preliminary
data futher suggest that APOBEC3A levels are
upregulated when SAMHD1 is depleted, raising the
possibility of a cooperation between the two restriction
factors to counteract the infection (data not shown).
The existence of several targets of Vpx has also been
suggested in monocyte-derived dendritic cells where
A
B
Figure 4 dNTP levels in CD4+ activated T cells are unaffected
by IFN-α. (A) CD4+ activated T cells derived from 4 donors’ PBMC
were either mock treated, or treated with a 1000 U/ml dose of IFN-α
for 24 h. The cells were then challenged with a HIV-1-GFP reporter
virus at MOI 4. The percentage of infection (% GFP + cells) was
measured 3 days post-transduction by flow cytometry. (B) The
intracellular dATP and dTTP levels were measured for one donor
using the single nucleotide-incorporation assay.
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C D
E
Figure 5 Vpx-mediated SAMHD1 degradation is inhibited by IFNs in THP-1 cells. (A) PMA-differentiated THP-1 cells were either mock treated,
or treated with IFN-α or IFN-γ (1000 U/ml) during 24 h, then were incubated with empty or Vpx-containing VLP (X- and X+) for 2 h. Subsequently, cells
were transduced with a VSV-G-pseudotyped GFP-encoding HIV-1 virus at MOI 1. The transduction rate was measured 3 days post-transduction
(upper panel) and protein expression analyzed (lower panel). The results shown here are representative of three independent experiments.
(B) SAMHD1-depleted THP-1 cells (shRNA SAMHD1) or control cells (shRNA scrambled scr) were treated with PMA, then primed with IFN-α (1000 U/ml)
for 24 h, before transduction with a HIV-1-Luc reporter virus. The luciferase activity was measured 2 days post-transduction (upper panel) and
SAMHD1 expression analyzed (lower panel). ND: not detected. (C) A monoclonal THP-1 cell line stably expressing HA-tagged SAMHD1 as well
as wt THP1 cells were differentiated by PMA. Cells were primed with IFN-α (1000 U/ml) for 24 h, before incubation for 2 h with empty or Vpx
containing VLP (X- or X+, respectively) and transduced with a HIV-1-Luc reporter virus. The luciferase activity was measured 2 days post-
transduction (upper panel). Levels of endogenous and HA-tagged SAMHD1 were analyzed by western blot (lower panel). ND: not detected. (D) PMA-
differentiated THP-1 cells were primed or not with IFN-α (10000 U/ml, 24 h). The BlaM-Vpr fusion entry test was then carried out as described in the
methods. (E) IFN-α does not modify SAMHD1 nuclear localization. PMA-differentiated THP-1 cells expressing or not HA-SAMHD1 were primed with
IFN-α (1000 U/ml) for 24 h. Cells were stained with the indicated antibodies for immunofluorescence (green). Nuclei were stained with DAPI (blue).
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Vpx was shown to rescue an IFN block that occurred
after HIV-1 cDNA penetrated the nucleus [53]. Den-
dritic cells may express specifically an antiviral protein
at higher levels than do MDMs.
The cellular factors that sustain the inhibition of HIV-1
transduction by IFN-α remain to be identified and the
mechanisms deciphered. Keeping in mind that IFN was
shown to affect cDNA accumulation in myeloid and CD4
primary T cells [10-18], we wondered whether treatment
with exogenous IFN-α would result in a depletion of the
nucleotide pool. Not only IFN-α had no measurable effect
on the dNTP pool at doses that inhibit HIV-1 transduc-
tion, but also Vpx still increased the dNTP pool in cells
treated with IFN-α. Therefore IFN-α does not appear to
cooperate with nucleotide depletion in MDMs to counter-
act HIV. Rather SAMHD1 and the interferon pathway
likely act in synergy to prevent the infection. Part of it
could be explained by the fact that the dNTP pool has to
be tightly regulated in the cell to avoid mutagenic or cyto-
toxic effects [61]. Nonetheless we have found that the
dNTP intracellular pool is reduced at high doses of IFN-α
(data not shown).
Surprisingly PMA treated-THP-1 cells model MDMs
in their sensitivity to Vpx toward HIV-1 transduction
but not in their ability to support Vpx-mediated
SAMHD1 degradation under IFN priming. We have
ruled out several hypotheses that could have explained
these differences, namely a transcriptional effect of IFN-α
from the SAMHD1 promoter, an effect of IFN-α on
SAMHD1 localization or on Vpx delivery in THP-1 cells.
Other hypothesizes should be explored, for instance the
involvement of the recently identified splice variants of
SAMHD1 [62] or the IFN-mediated upregulation of host
factors specifically in THP-1 cells that would disrupt Vpx-
mediated SAMHD1 degradation. The discovery of the
mechanism at stake should help to decipher the regulation
of SAMHD1 restriction activity.
Methods
Cells and cell culture
PBMCs from the blood of anonymous donors (obtained
in accordance with the ethical guidelines of the Institut
Cochin, Paris) were obtained by Ficoll density-gradient
separation. Monocytes were isolated by positive selection
on CD14 magnetic microbeads (Miltenyi Biotec) and
CD4+ T cells were isolated by positive selection with
CD4 magnetic microbeads (Milteny Biotec), followed by
culture in BD Primaria flasks with R10 medium (RPMI-
1640 GlutaMAX-I, 10 mM HEPES, pH 7.2, 1 mM
sodium pyruvate, 1% (vol/vol) nonessential amino acids
and 10% (vol/vol) heat-inactivated FCS) and antibiotics.
MDMs were obtained from monocytes by culture of the
cells for 7–9 d with granulocyte-macrophage colony-
stimulating factor (10 ng/ml) and macrophage colony-
stimulating factor (20 ng/ml). The primary CD4+ T cells
were activated with phytohemaglutinin A (PHA-L;
3.0 mg/mL; Sigma-Aldrich) and interleukin-2 (IL2;
50 IU/mL; PeproTech) for 2 days prior to treatment
with 1000 U/ml of IFN-α for 24 h. Human monocytic
THP-1 cells and lymphoid Jurkat and CEM cells were
maintained in R10 medium. THP-1 cells were differenti-
ated with a 65 nM phorbol 12-myristate 13-acetate
(PMA) treatment for 24 h. A THP-1-HA-SAMHD1
polyclonal cell line was obtained after cell transduction
with viral particles expressing HA-SAMHD1 from the
pLenti vector [27] and puromycin selection (2 μg/ml for
2 weeks). A monoclonal cell line was further developed
by plating one cell expressing HA-SAMHD1 per well
with the help of a flow cytometer. SAMHD1-depleted
THP-1 cells were previously described [28].
Viruses and virus-like particles (VLP) production
VLP and viruses were produced in 293 T cells co-
transfected by the calcium-phosphate method according
to Berger et al. [45,63]. Vpx-containing and control
SIVmac VLP were produced by transfection of 293 T
cells with pSIV3+ Δvpr (VLPs X+) or pSIV3+ Δvpx Δvpr
(VLP X−) [52] along with a plasmid encoding for vesicu-
lar stomatitis virus glycoprotein (VSV-G) in a ratio of
10:1. For the SIVmac-GFP reporter virus, the minimal
SIVmac genome pGAE 1.0, in which GFP expression is
driven from the cytomegalovirus promoter, was added to
the packaging and VSV-G encoding plasmids in a ratio
of 5:5:1 [45,63]. The HIV-1-GFP and HIV-1-Luc viruses
were produced by transfection of cells with pRRLsin.
eGFP and pCTS.Luc plasmids, respectively, with
pCMVΔR8.91 packaging and VSV-G plasmids, in a
ratio of 5:5:2 [45,63,64]. β-lactamase-Vpr (BlaM-Vpr)
containing particles were produced by transfection of
cells with the pCMV-BlaM-Vpr plasmid along with the
pCMVΔR8.91 packaging and the VSV-G encoding
vectors [65,66]. The culture supernatants were collected
48 h and 72 h after transfection and passed through
0.45-μm pore filters. The viral particles were then con-
centrated in 10% polyethylene glycol 6000 (PEG-6000)
(Sigma) containing 300 mM NaCl and titrated by
quantification of HIV-1 p24 and SIV p27 capsid
using an enzyme-linked immunosorbent assay (ELISA)
(ZeptoMetrix Corp.). Blam-Vpr containing particles
were concentrated by ultracentrifuged through a 25%
sucrose cushion in TNE buffer (100 mM NaCl, 10 mM
Tris-HCl, pH 7.4, and 1 mM EDTA) at 150000 X g for
1 h. All viruses were normalized by single-cycle infectiv-
ity assays on HeLa cells.
Transductions
Cells were transduced as described before for infection
of dendritic cells [63]. Cells were preincubated with VLP
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for 2 h, then, when required, transduced with the indi-
cated virus. The minimal amount of VLP (X+) required
for maximal helper effect for HIV-1 infection was deter-
mined by functional titration. After preincubation, cells
were infected for 2 h with the indicated reporter virus at a
multiplicity of infection (MOI) of 1. Where indicated,
infected cells were treated for 20 h with deoxynucleosides,
which consisted of a mixture of dA (D8668), dC (D0776),
dG (D0901) and dT (T1895; all from Sigma-Aldrich) as
previously described [27].
Western blot procedure and antibodies
Cells were lysed in adequate volumes of M-PER buffer
(Pierce) containing 150 mM NaCl and an anti-protease
mixture (Sigma) [67]. Protein extracts were separated by
SDS-PAGE electrophoresis, transferred onto PVDF
membranes, and revealed by a chemiluminescence pro-
cedure (CDPStarW, Applied Biosystems). Signals were
acquired by a LAS 3000 apparatus (Fujifilm) for further
analysis using the Multigauge software (Fujifilm). The
following antibodies were used: monoclonal anti-HA tag
antibody [16B12], anti-SAMHD1 [1 F9], and anti-ISG15
[3E5] from Abcam; monoclonal anti-α-Tubulin and anti-
Actin from Sigma, monoclonal anti-β-Catenin from BD
Bioscience, and polyclonal anti-A3G Apo-C17 antibody
that recognizes both A3G and A3A (recognized for its
smaller size, [59]) from the AIDS Reagents and Refer-
ence Program of the NIH.
Quantification of whole-cell dNTP pools
The dNTP were quantified as previously described [40].
Briefly, cells were harvested and lysed in cold 65% aque-
ous methanol, vortexed vigorously, and heated to 95°C
for 5 min. Cellular debris were removed from the sample
through centrifugation at 13,000 rpm for 3 min. Super-
natant was removed and dried in a speed vacuum. The
dried samples were suspended in (50 mM Tris-HCl,
pH 8.0, and 10 mM MgCl2). Extracts were incubated
with 200 fmol of primer/template. An 18-nucleotide
primer labeled at the 50 end with 32 P (50-GTC
CCTGTTCGGGCGCCA-30) was annealed at a 1:2 ratio
to four different 19-nucleotide templates (50-NTGGCG
CCCGAACAGGGAC-30), where ‘N’ represents dG, dC,
dA or dC. The reactions contained 2 μl of dNTP cell
extract, 4 μl of excess HIV-1 RT, 25 mM Tris–HCl,
pH 8.0, 2 mM dithiothreitol, 100 mM KCl, 5 mM
MgCl2, and 10 μM oligo(dT) to a final volume of 20 μL.
Reactions were incubated for 5 min at 37°C and termi-
nated using 10 μl 40 mM EDTA, 99% formamide and
heated at 95°C for 5 min. For analysis, reaction products
were separated on a 14% polyacrylamide-urea denaturing
gel (SequaGel, National Diagnostics) and analyzed on a
PhosphorImager (PerkinElmer). Product extension was
quantified by densitometry (Quantity One) and dNTP
amount was calculated based on accountability of the
dNTP sample dilution factor, so that each sample
volume was adjusted to obtain a signal within the linear
range of the assay’s standard curve.
BlaM-Vpr entry test
The BlaM-Vpr entry test was performed as described in
[65] by measuring enzymatic cleavage of a β-lactamase
substrate (CCF2/AM, Invitrogen) loaded in target cells.
Briefly, cells were incubated with HIV-1 VLP containing
the BlaM-Vpr fusion protein for 2 h at 37°C. Cells were
then incubated in CO2-independent medium containing
the CCF2/AM β-lactamase substrate at room temperature
in the dark for 12 hours before fixation and analysis by
flow cytometry.
Immunofluorescence
THP-1 cell monolayers were differentiated with PMA for
24 h on coverslips, then treated or not with 1000 U/ml
IFN-α for 24 h. After washing and fixing as decribed in
[68], cells were permeabilized for 3 + 15 min with PBT
buffer (0.2% Tween 20, 1% bovine serum albumin in PBS).
Subsequently, cells were incubated for 1 h at room
temperature with primary antibodies in PBT buffer (Alexa
FluorW 488 anti-HA antibody (Invitrogen), or anti-
SAMHD1 antibody [3 F5] (ab119751, Abcam). After three
washes with PBS, when required, the cells were incubated
for 30 min with secondary antibodies. Nuclei were stained
with DAPI in mounting media (Vectashield; Vector
Laboratories). Images were collected on a Zeiss Axio
Observer.Z1 microscope using a 100X oil immersion
objective, and analyzed with Metamorph 7 (Molecular
Devices).
Additional file
Additional file 1: Figure S1. Western blot analysis of SAMHD1
expression in monocytes and MDMs (from Figure 1A and B) was carried
out 3 days after IFN priming (one representative Western blot is shown
for each cell type).
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